Contrasting AVITA MED LTD/S (NASDAQ:RCEL) & Rubius Therapeutics (NASDAQ:RUBY)

Rubius Therapeutics (NASDAQ:RUBY) and AVITA MED LTD/S (NASDAQ:RCEL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, valuation and earnings.

Insider & Institutional Ownership

0.0% of AVITA MED LTD/S shares are held by institutional investors. 58.4% of Rubius Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings for Rubius Therapeutics and AVITA MED LTD/S, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rubius Therapeutics 1 0 4 0 2.60
AVITA MED LTD/S 0 0 1 0 3.00

Rubius Therapeutics currently has a consensus target price of $25.00, indicating a potential upside of 208.26%. AVITA MED LTD/S has a consensus target price of $12.00, indicating a potential upside of 51.13%. Given Rubius Therapeutics’ higher probable upside, research analysts plainly believe Rubius Therapeutics is more favorable than AVITA MED LTD/S.

Valuation and Earnings

This table compares Rubius Therapeutics and AVITA MED LTD/S’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Rubius Therapeutics N/A N/A -$89.19 million ($2.27) -3.57
AVITA MED LTD/S $5.51 million 119.06 -$24.75 million ($0.39) -20.36

AVITA MED LTD/S has higher revenue and earnings than Rubius Therapeutics. AVITA MED LTD/S is trading at a lower price-to-earnings ratio than Rubius Therapeutics, indicating that it is currently the more affordable of the two stocks.


This table compares Rubius Therapeutics and AVITA MED LTD/S’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Rubius Therapeutics N/A -41.30% -32.65%

Risk and Volatility

Rubius Therapeutics has a beta of 2.15, meaning that its stock price is 115% more volatile than the S&P 500. Comparatively, AVITA MED LTD/S has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500.


AVITA MED LTD/S beats Rubius Therapeutics on 7 of the 12 factors compared between the two stocks.

About Rubius Therapeutics

Rubius Therapeutics, Inc. focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing various RCTs, such as RTX-134 for treatment of phenylketonuria; RTX-Uricase for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; and RTX-OxOx for the treatment of second-line hyperoxaluria. It is also developing RTX-240 and RTX-224 for the treatment of cancer; and RTX-aAPC to treat solid and hematological cancers. In addition, the company is developing RTX-T1D for treating type 1 diabetes; and RTX-PV for treating pemphigus vulgaris. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.


Avita Medical Limited operates as a regenerative medicine company in the Asia Pacific, Europe, the Middle East, Africa, and the Americas. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients 18 years and older. The company is based in Valencia, California.

Receive News & Ratings for Rubius Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rubius Therapeutics and related companies with's FREE daily email newsletter.